Nucleosides with anti-hepatitis B virus activity

Details Nucleosides with anti-hepatitis B virus activity Nucleosides with anti-hepatitis B virus activity

2001-06-12

2008-12-23

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S045000, C514S046000, C514S048000

Reexamination Certificate

active

07468357

ABSTRACT:
A method for the treatment of a host, and in particular, a human, infected with hepatitis B virus (HBV) is provided that includes administering an effective amount of a β-L-nucleotide, optionally in combination therapy with other drugs for the treatment of HBV or human immuno-deficiency virus (HIV).

REFERENCES:
patent: 4000137 (1976-12-01), Dvonch et al.
patent: 4140761 (1979-02-01), Gerin et al.
patent: 4336381 (1982-06-01), Nagata et al.
patent: 4788181 (1988-11-01), Driscoll et al.
patent: 4818538 (1989-04-01), Rideout et al.
patent: 4861759 (1989-08-01), Mitsuya et al.
patent: 4879277 (1989-11-01), Mitsuya et al.
patent: 4900828 (1990-02-01), Belica et al.
patent: 4916122 (1990-04-01), Chu et al.
patent: 4963533 (1990-10-01), de Clercq et al.
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5059690 (1991-10-01), Zahler et al.
patent: 5089500 (1992-02-01), Daluge
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5151426 (1992-09-01), Belleau et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5185437 (1993-02-01), Koszalka et al.
patent: 5194654 (1993-03-01), Hostetler et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5223263 (1993-06-01), Hostetler et al.
patent: 5234913 (1993-08-01), Furman, Jr. et al.
patent: 5248776 (1993-09-01), Chu et al.
patent: 5256641 (1993-10-01), Yatvin et al.
patent: 5270315 (1993-12-01), Belleau et al.
patent: 5276151 (1994-01-01), Liotta
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5444063 (1995-08-01), Schinazi
patent: 5463092 (1995-10-01), Hostetler et al.
patent: 5466806 (1995-11-01), Belleau et al.
patent: 5486520 (1996-01-01), Belleau et al.
patent: 5532246 (1996-07-01), Belleau et al.
patent: 5539116 (1996-07-01), Liotta et al.
patent: 5543389 (1996-08-01), Yatvin et al.
patent: 5543390 (1996-08-01), Yatvin et al.
patent: 5543391 (1996-08-01), Yatvin et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5561120 (1996-10-01), Lin et al.
patent: 5587480 (1996-12-01), Belleau et al.
patent: 5604209 (1997-02-01), Ubasawa et al.
patent: 5627160 (1997-05-01), Lin et al.
patent: 5631239 (1997-05-01), Lin et al.
patent: 5696254 (1997-12-01), Mansour et al.
patent: 5744596 (1998-04-01), Mansour et al.
patent: 5756706 (1998-05-01), Mansour et al.
patent: 5770713 (1998-06-01), Imbach et al.
patent: 5770725 (1998-06-01), Gosselin et al.
patent: 5849905 (1998-12-01), Gosselin et al.
patent: 5852027 (1998-12-01), Liotta et al.
patent: 5990093 (1999-11-01), Schinazi et al.
patent: 6156737 (2000-12-01), Mansour et al.
patent: 6245749 (2001-06-01), Schinazi et al.
patent: 0 217 580 (1987-04-01), None
patent: 0 337 713 (1989-10-01), None
patent: 0 433 898 (1989-12-01), None
patent: 0 350 287 (1990-01-01), None
patent: 0 352 248 (1990-01-01), None
patent: 0 375 329 (1990-06-01), None
patent: 0 382 526 (1990-08-01), None
patent: 0 494 119 (1992-08-01), None
patent: 0 515 144 (1992-11-01), None
patent: 0 515 156 (1992-11-01), None
patent: 0 515 157 (1992-11-01), None
patent: 0 526 253 (1993-02-01), None
patent: WO 88/07532 (1988-10-01), None
patent: WO 88/08001 (1988-10-01), None
patent: WO 89/02733 (1989-04-01), None
patent: WO 90/00555 (1990-01-01), None
patent: WO 90/12023 (1990-10-01), None
patent: WO 91/11186 (1991-08-01), None
patent: WO 91/16920 (1991-11-01), None
patent: WO 91/17159 (1991-11-01), None
patent: WO 91/18914 (1991-12-01), None
patent: WO 91/19721 (1991-12-01), None
patent: WO 92/00315 (1992-01-01), None
patent: WO 92/06102 (1992-04-01), None
patent: WO 92/08717 (1992-05-01), None
patent: WO 92/10496 (1992-06-01), None
patent: WO 92/10497 (1992-06-01), None
patent: WO 92/14729 (1992-09-01), None
patent: WO 92/14743 (1992-09-01), None
patent: WO 92/15308 (1992-09-01), None
patent: WO 92/18517 (1992-10-01), None
patent: WO 92/21676 (1992-12-01), None
patent: WO 93/00910 (1993-01-01), None
patent: WO 93/12128 (1993-06-01), None
patent: WO 93/12131 (1993-06-01), None
patent: WO 93/12132 (1993-06-01), None
patent: WO 93/24510 (1993-12-01), None
patent: WO 94/04154 (1994-03-01), None
patent: WO 94/05300 (1994-03-01), None
patent: WO 94/09793 (1994-05-01), None
patent: WO 94/14456 (1994-07-01), None
patent: WO 94/14802 (1994-07-01), None
patent: WO 94/26273 (1994-11-01), None
patent: WO 94/26764 (1994-11-01), None
patent: WO 94/27616 (1994-12-01), None
patent: WO 95/07287 (1995-03-01), None
patent: WO 95/11252 (1995-04-01), None
patent: WO 95/20595 (1995-08-01), None
patent: WO 96/15132 (1996-05-01), None
patent: WO 96/40164 (1996-12-01), None
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill Medical Publishing Division, 2001, pp. 54-56.
Ayoola, et al., “Progress in the Control of Viral Hepatitis: Memorandum from a WHO Meeting,”Bulletin of the World Health Organization, 66(4):443-455 (1988).
Beach, et al., “Synthesis of Enantiomerically Pure (2′R,5′S)-(—)-1-]2-(hydroxymethyl)oathiolan-5-yl]Cytosine as a Potential Antiviral Agent Against Hepatitis B (HBV) and Human Immunodeficiency,”J. Org. Chem. 57:2217-2219 (1992).
Beasley, et al., “Hepatocellular Carcinoma and Hepatitis B Virus,”The Lancet, 1129-1133 (1981).
Belleau, B., et al., “Design and Activity of a Novel Class of Nucleoside Analogs Effective Against HIV-1 . . . ,”Intl. Conf. on AIDS, Montreal, Quebec, Canada, Jun. 4-9, 1989.
Boutelje, et al.,Chemical Abstracts108:128048 (1987).
Chang, C-N., et al., “Biochemical Pharmacology of (+) and (−)-2′,3′-Dideoxy-3′-Thiacytidine as Anti-Hepatitis B Virus Agents,”J. Biol. Chem. 267(31):22414-22420 (1992).
Chang, Chien-Neng, et al., “Deoxycytidine Deaminase-resistant Steroisomer is the Active Form of (+)-2′-3′-Dideoxy S′-Thiacytidine in the Inhibition of Hepatitis B Virus Replication,”J. Bio. Chem., 267(20):13938-13942 (1992).
Chang, Chungming, et al., “Production of Hepatitis B Virus in vitro by Transient Expression of cloned HBV PNA in Hepatoma Cell Line,”The EMBO J. 6(3):675-680 (1987).
Chu, et al., “Structure Activity Relationships of Pyrimiding Nucleosides as Antiviral Agents for Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells.”J. Med. Chem.; 32:3 pp. 612-617 (1989).
Chu, et al., “Enantiomeric Synthesis of (+)-BCH-189[(+)-(2S,5R)-I-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine] from D-Mannose and Its Anti-HIV Activity,”J. Org. Chem., 56:6503-6505 (1991).
Chu, et al., “An Efficient Total Synthesis of 3′-Azido-3′-Deoxythiymidine (AZT) and 3′-Azido-2′,3′-Dideoxyuridine (AZDDU, CS-87) fromD-Mannitol,”Tetrahedron Letters, 29(42):5349-5352 (1988).
Chu, et al., “Comparative Activity of 2′,3′-Saturated and Unsaturated Pyrimidine and Purine Nucleosides Against Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells,”Biochem. Pharm. 37(19); pp. 3543-3548 (1988).
Chu, et al., “Synthesis and Biological Evaluation of D-(2S) and L-(2R)-I,3-Oxathiolanyl-and D-(2R)- and L-(2S)-I,3-Dioxolanyl-Nucleosides as Anti-HIV and Anti-HBV Agents,”Antiviral Research, 30(S1): 192; p. 146 (1993).
Chu, et al., “Synthesis and Anti-HIV and Anti-HBV Activity of Enantiomerically Pure Oxathiolane Nucleosides,”Antiviral Research, 17(S1):2; p. 44 (1992).
Chu, et al., “Asymmetric Synthesis of Enantiomerically Pure (+)-(I′R,4′R)-Dioxolane-thymine and Its Anti-HIV Activity,”Tetrahedron Letters, 32(31):3791-3794 (1991).
Coates, et al., “The Separated Enaniomers of 2′-Deoxy-3′-Thiacytidine (BCH-189) Both Inhibit Human Immunodeficiency Virus Replication In Vitro,”Antimicrob. Agents Chemother. 36(1):202-205 (1992).
Cretton, et al., “Catabolism of 3′-Azido-3′-Deoxythymidine in Heptaocytes and Liver Microsomes, with Evidence of Formation of 3′-Amino-3′-Deoxythymidine a Highly Toxic Catabolite f

Affiliated with

Also associated with

Rating

Nucleosides with anti-hepatitis B virus activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleosides with anti-hepatitis B virus activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleosides with anti-hepatitis B virus activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4023119